Year: 2021
Type: article
Abstract: Using transcriptional profiling, three robust subtypes of nonsquamous non–small cell lung cancer were defined, independently of initiating oncogenic driver events. Subtype-specific differential sensitivity to MEK1/2 inhibitors was reported and an interaction between the mucinous subtype, STK11/LKB1 genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified. See related article by Daemen et al., p. 1162
Source: Clinical Cancer Research
Author: Ferdinandos Skoulidis
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3111703900